自发性脑出血血肿扩大机制及止血治疗进展  

Progress on hematoma expansion mechanism and hemostatic therapy of spontaneous intracerebral hemorrhage

作　　者：李育健 郑峻[1] LI Yu-jian;ZHENG Jun(Department of Neurosurgery,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China)

机构地区：[1]四川大学华西医院神经外科,成都610041

出　　处：《中国现代神经疾病杂志》2021年第2期94-100,共7页Chinese Journal of Contemporary Neurology and Neurosurgery

基　　金：国家自然科学基金青年科学基金资助项目(项目编号:81801186);四川省区域创新合作项目(项目编号:2020YFQ0009)。

摘　　要：自发性脑出血是一种严重的脑卒中亚型,大多数患者发病短期即可出现血肿扩大,导致神经系统症状恶化和病死,因此早期止血治疗对挽救患者生命、改善预后至关重要。目前用于脑出血的止血药以抗纤溶类药物和重组凝血因子Ⅶa为主,但至今尚未获得脑出血患者可从止血药治疗中获益的临床证据。本文对自发性脑出血血肿扩大机制和常用止血药研究进展进行概述,以为临床选择用药提供参考。Spontaneous intracerebral hemorrhage(SICH) is a severe subtype of stroke. Hematoma expansion could occur in the short term after symptom onset in most patients, leading to neurological deterioration and mortality. Therefore, early hemostasis treatment is essential to save patients’ lives and improve prognosis. Currently, the hemostatic agents used for intracerebral hemorrhage are mainly antifibrinolytic drugs and recombinant activated factor Ⅶ. However, there is no decisive evidence for the clinical benefit of hemostatic drugs in patients with intracerebral hemorrhage. To provide reference for clinical choice of drugs, this article reviews the hematoma expansion mechanism and hemostatic therapy of spontaneous intracerebral hemorrhage.

关 键 词：脑出血 血肿 止血药 综述 

分 类 号：R743.34[医药卫生—神经病学与精神病学]